Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06322238
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-21
First Post:
2024-02-09
Brief Title:
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
A Multi-gene Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice Open-label Mayo Clinic Multisite Mankato-Rochester Primary Care Controlled Implementation Study Taking the Results of the PREPARE Study Into Minnesota PREPARE-Mayo
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PREPARE-Mayo
Brief Summary:
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic PGx testing of a panel of clinically relevant PGx markers to guide the dose and drug selection for 39 commonly prescribed drugs will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion referred to as index drug
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None